Segmentation by type delineates the material origins and engineering approaches that underpin the Active Biological Bone market. Autograft products, harvested from the patient’s own tissue, occupy a niche yet high‑value segment due to superior immunocompatibility, contributing approximately 25 % of sales despite limited supply. Allograft materials, processed from donor bone, represent the largest share at about 35 %, balancing availability with retained osteoinductive factors. Xenograft sources, typically bovine or porcine, add roughly 10 % as cost‑effective alternatives, though they require extensive deproteinization to mitigate immune response. Synthetic options—principally calcium phosphate ceramics and bioactive glass—account for 20 % of the market, offering customizable porosity and resorption rates. Composite constructs, which combine biological matrices with synthetic polymers or growth‑factor carriers, comprise the remaining 10 %, reflecting emerging interest in multifunctional scaffolds that deliver mechanical strength alongside controlled biological activity. Each type’s proportion reflects its clinical acceptance, manufacturing complexity, and cost structure, together shaping overall market dynamics.